tailieuchung - A phase II study of the PI3K inhibitor copanlisib in combination with the antiCD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: Treatment rationale and protocol design of the COUP-1 trial

Đang chuẩn bị liên kết để tải về tài liệu:
A phase II study of the PI3K inhibitor copanlisib in combination with the antiCD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: Treatment rationale and protocol design of the COUP-1 trial

Mỹ Hoàn 56 8 pdf

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ Tải xuống

Advanced stage marginal zone lymphoma (MZL) is an incurable indolent B-cell lymphoma, for which a wide variety of treatments ranging from single agent rituximab to more dose intense immunochemotherapy exists. |

Đang chuẩn bị liên kết để tải về tài liệu:
A phase II study of the PI3K inhibitor copanlisib in combination with the antiCD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: Treatment rationale and protocol design of the COUP-1 trial

Advanced stage marginal zone lymphoma (MZL) is an incurable indolent B-cell lymphoma, for which a wide variety of treatments ranging from single agent rituximab to more dose intense immunochemotherapy exists. |

NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: Study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: A phase II study

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

Examestane in advanced or recurrent endometrial carcinoma: A prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: Update on a phase II study

The WIRE study a phase II, multi-arm, multicentre, non-randomised window-ofopportunity clinical trial platform using a Bayesian adaptive design for proof-ofmechanism of novel treatment strategies in operable renal cell cancer – a study protocol

Đang chuẩn bị liên kết để tải về tài liệu: A phase II study of the PI3K inhibitor copanlisib in combination with the antiCD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: Treatment rationale and protocol design of the COUP-1 trial

Advanced stage marginal zone lymphoma (MZL) is an incurable indolent B-cell lymphoma, for which a wide variety of treatments ranging from single agent rituximab to more dose intense immunochemotherapy exists. |

NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: Study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: A phase II study

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

Examestane in advanced or recurrent endometrial carcinoma: A prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: Update on a phase II study

The WIRE study a phase II, multi-arm, multicentre, non-randomised window-ofopportunity clinical trial platform using a Bayesian adaptive design for proof-ofmechanism of novel treatment strategies in operable renal cell cancer – a study protocol

Đang chuẩn bị liên kết để tải về tài liệu:
A phase II study of the PI3K inhibitor copanlisib in combination with the antiCD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: Treatment rationale and protocol design of the COUP-1 trial